The euro stablecoin market has surged from about €50 million in early 2024 to $835 million by mid-2026, with Ethereum, Solana, and Base dominating 91.5% of the market share. Ethereum leads with nearly 70%, followed by Solana at 14.8%, and Base at 6.9%. Most euro stablecoins now comply with MiCA regulations, with Circle's EURC and SG Forge's EURCV tokens making up over 80% of the supply. Other blockchains hold less than 9% combined, highlighting the concentrated nature of this market segment.
Euro stablecoins dominate with a 91.5% market share concentrated in Ethereum, Solana, and Base. For readers following cryptocurrency markets, here is Pluang's snapshot as of Sep 14, 2026 18:51 WIB: out of 50 major cryptocurrencies tradable on Pluang, 33 rose and 15 fell today. Notable movers include ADA (Cardano) at Rp3.715 with a 3.25% increase and 88% buy order activity, SUSHI (SushiSwap) at Rp3.864 down 3.12%, and ENJ (Enjin Coin) at Rp462 down 3.03%.
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings Inc and Omico have formed a partnership to accelerate precision oncology research in Australia by connecting cancer patients to biomarker-driven clinical trials. The collaboration combines Fortrea's expertise in oncology clinical tri...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
Fortrea Holdings Inc and Omico have formed a partnership to enhance precision oncology research in Australia by matching cancer patients with biomarker-driven clinical trials. This collaboration combines Fortrea's expertise in oncology clinical trial...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research by improving biomarker-based clinical trial planning and patient recruitment in Australia. The collaboration leverages Fortrea's clinical trial expertise a...
